Pfizer is heavily investing in its experimental obesity drug, danuglipron, aiming for a once-daily oral pill to compete with the currently dominant injectable weight-loss treatments from Eli Lilly and Novo Nordisk. CEO Albert Bourla expressed cautious optimism, anticipating data from dose-testing studies within months and a potential market entry as the second oral option. While Pfizer is not pursuing acquisitions in the injectable GLP-1 market, they remain open to acquiring other types of obesity treatments. The company's goal is to provide a convenient and competitive alternative in a market projected to reach $150 billion annually by the early 2030s. The unrelated mention of a \"Bio Leg\" device suggests extraneous information included in the source material.
","author_name":"Dr. Kesha Chauhan, MD"}